---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097894"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:17:21.190991+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit

## Summary
- Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.
- Net loss narrowed to $134,272 from $3.37M; EPS improved to -$0.02 from -$0.82.
- Cash balance grew to $137,344 vs $60,155 at year-end 2023.
- Achieved first operational profit but higher interest from convertible debt kept EPS negative.
- Licensing agreements could provide up to $292 million; $496K milestone cash received in 9 months.

## SEC filing metadata
- accession: 0001213900-24-097894
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/0001213900-24-097894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024097894/ea0221143-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097894
- JSON: https://secwatch.observer/filing/0001213900-24-097894.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.